JP2007529997A - 機能的インフルエンザウイルス様粒子（ｖｌｐ） - Google Patents

機能的インフルエンザウイルス様粒子（ｖｌｐ） Download PDF

Info

Publication number
JP2007529997A
JP2007529997A JP2006518925A JP2006518925A JP2007529997A JP 2007529997 A JP2007529997 A JP 2007529997A JP 2006518925 A JP2006518925 A JP 2006518925A JP 2006518925 A JP2006518925 A JP 2006518925A JP 2007529997 A JP2007529997 A JP 2007529997A
Authority
JP
Japan
Prior art keywords
protein
influenza
influenza virus
virus
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006518925A
Other languages
English (en)
Japanese (ja)
Inventor
ロビン エー． ロビンソン，
ピーター エム． プシュコ，
Original Assignee
ノババックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノババックス インコーポレイテッド filed Critical ノババックス インコーポレイテッド
Publication of JP2007529997A publication Critical patent/JP2007529997A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
JP2006518925A 2003-07-11 2004-07-09 機能的インフルエンザウイルス様粒子（ｖｌｐ） Withdrawn JP2007529997A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/617,569 US8592197B2 (en) 2003-07-11 2003-07-11 Functional influenza virus-like particles (VLPs)
PCT/US2004/022001 WO2005020889A2 (en) 2003-07-11 2004-07-09 Functional influenza virus-like particles (vlps)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010208644A Division JP2011046715A (ja) 2003-07-11 2010-09-16 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2014258346A Division JP2015057447A (ja) 2003-07-11 2014-12-22 機能的インフルエンザウイルス様粒子（ｖｌｐ）

Publications (1)

Publication Number Publication Date
JP2007529997A true JP2007529997A (ja) 2007-11-01

Family

ID=33565000

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006518925A Withdrawn JP2007529997A (ja) 2003-07-11 2004-07-09 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2010208644A Pending JP2011046715A (ja) 2003-07-11 2010-09-16 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2013141285A Withdrawn JP2013216685A (ja) 2003-07-11 2013-07-05 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2014258346A Withdrawn JP2015057447A (ja) 2003-07-11 2014-12-22 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2016110634A Pending JP2016164195A (ja) 2003-07-11 2016-06-02 機能的インフルエンザウイルス様粒子（ｖｌｐ）

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010208644A Pending JP2011046715A (ja) 2003-07-11 2010-09-16 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2013141285A Withdrawn JP2013216685A (ja) 2003-07-11 2013-07-05 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2014258346A Withdrawn JP2015057447A (ja) 2003-07-11 2014-12-22 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2016110634A Pending JP2016164195A (ja) 2003-07-11 2016-06-02 機能的インフルエンザウイルス様粒子（ｖｌｐ）

Country Status (19)

Country Link
US (5) US8592197B2 (cg-RX-API-DMAC7.html)
EP (2) EP2343084B1 (cg-RX-API-DMAC7.html)
JP (5) JP2007529997A (cg-RX-API-DMAC7.html)
KR (1) KR101153929B1 (cg-RX-API-DMAC7.html)
CN (3) CN103157103A (cg-RX-API-DMAC7.html)
AT (1) ATE538810T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004268510B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412519A (cg-RX-API-DMAC7.html)
CA (1) CA2532335C (cg-RX-API-DMAC7.html)
DK (2) DK1644037T3 (cg-RX-API-DMAC7.html)
ES (2) ES2380021T3 (cg-RX-API-DMAC7.html)
IL (1) IL173071A (cg-RX-API-DMAC7.html)
MX (1) MXPA06000469A (cg-RX-API-DMAC7.html)
NZ (1) NZ544580A (cg-RX-API-DMAC7.html)
PL (2) PL2343084T3 (cg-RX-API-DMAC7.html)
PT (2) PT2343084E (cg-RX-API-DMAC7.html)
RU (1) RU2369405C2 (cg-RX-API-DMAC7.html)
SG (2) SG131116A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005020889A2 (cg-RX-API-DMAC7.html)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519849A (ja) * 2011-06-20 2014-08-21 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
WO2016010081A1 (ja) * 2014-07-18 2016-01-21 一般財団法人化学及血清療法研究所 ウイルス様粒子を含むワクチン
JP2016104015A (ja) * 2009-05-01 2016-06-09 ファイザー・インク 多重遺伝子ベクターによってコードされる組換えウイルス様粒子
JP2018530314A (ja) * 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
US11384339B2 (en) 2011-08-26 2022-07-12 Wisconsin Alumni Research Foundation (Warf) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
US11802273B2 (en) 2014-06-20 2023-10-31 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US12076387B2 (en) 2010-03-23 2024-09-03 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US12122807B2 (en) 2019-05-01 2024-10-22 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US12144857B2 (en) 2018-08-20 2024-11-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US12251436B2 (en) 2017-10-25 2025-03-18 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US12365880B2 (en) 2020-01-24 2025-07-22 The University Of Tokyo Recombinant influenza viruses with stabilized NA
US12364748B2 (en) 2016-02-19 2025-07-22 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
US8206950B2 (en) * 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US20090208517A1 (en) * 2004-08-19 2009-08-20 Bernhard Moser Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy
JP5016489B2 (ja) * 2004-08-19 2012-09-05 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 抗原提示ヒトγδＴ細胞の調製及び免疫療法における使用
MX2007010008A (es) * 2005-02-16 2008-01-18 Lentigen Corp Vectores lentivirales y su uso.
BRPI0610503B1 (pt) 2005-04-21 2022-05-31 University Of Florida Research Foundation Composições compreendendo vírus influenza, polinucleotídeo isolado, polipeptídeo ou vírus reagrupado, bem como construção de expressão de polinucleotídeo, oligonucleotídeo, micro-organismo transgênico, e métodos para a detecção de um vírus influenza que é capaz de infectar um animal canídeo
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
CA2625406C (en) * 2005-10-18 2016-08-09 Novavax, Inc. Functional influenza virus like particles (vlps)
KR101548436B1 (ko) 2005-10-19 2015-08-28 코넬 리서치 화운데이션,인크. 개과 동물의 호흡기 질병 조절을 위한 물질들 및 방법들
WO2008048269A2 (en) * 2005-10-20 2008-04-24 Combimatrix Corporation Microarray for pathogen identification
GB2432419A (en) * 2005-11-16 2007-05-23 Agency Science Tech & Res Influenza A virus detection method
FI20051255A0 (fi) * 2005-12-05 2005-12-05 Pekka Untamo Heino Seuraavaa influenssa A-pandemiaa vastaan soveltuva rokote
US8232058B2 (en) * 2006-01-20 2012-07-31 Lawrence Livermore National Security, Llc Multiplex detection of respiratory pathogens
KR101492524B1 (ko) * 2006-02-02 2015-02-12 글로브이뮨 면역 반응 유도를 위한 효모-기반 백신
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
EP2476432B1 (en) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126788A2 (en) * 2006-03-27 2007-11-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the treatment and prevention of viral infection
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
WO2007130327A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
KR100702034B1 (ko) * 2006-05-12 2007-03-30 삼성전자주식회사 반도체 장치, 이 장치의 전원 노이즈 감소 방법 및 인쇄회로 기판
WO2008036146A2 (en) 2006-07-14 2008-03-27 Sanofi Pasteur Biologics Co. Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
CA2659275C (en) 2006-07-27 2017-01-10 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US20090098527A1 (en) * 2006-09-12 2009-04-16 Fischer Gerald W Biological organism identification product and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) * 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
JP2010504760A (ja) 2006-09-29 2010-02-18 サノフィ パスツール バイオロジクス カンパニー 組換え型ライノウイルスベクター
AU2007303608B2 (en) 2006-09-29 2013-05-02 Takeda Vaccines, Inc. Norovirus vaccine formulations
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2175883A4 (en) * 2007-07-19 2011-11-30 Novavax Inc CHIMERIC VARICELLA ZOSTER VIRUS-VIRUSUAL PARTICLES
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) * 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
WO2009085355A2 (en) 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
KR20100120157A (ko) 2007-11-27 2010-11-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
WO2009102229A1 (ru) * 2008-02-15 2009-08-20 A.N. Belozersky Institute Of Physico-Chemical Biology, Moscow State University Липид-протеиновый рафтовый комплекс из оболочки вируса гриппа а для противогриппозных вакцин и способ его выделения, способ получения вирусоподобных частиц из таких комплексов
CN102137675A (zh) 2008-04-17 2011-07-27 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
WO2009128951A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of respiratory synctial virus proteins and methods of use
WO2009135152A2 (en) 2008-05-02 2009-11-05 University Of Rochester Arrayed detector system for measurement of influenza immune response
US8450056B2 (en) * 2008-05-02 2013-05-28 University Of Rochester Arrayed imaging reflectometry (AIR) sensor chip comprising virus-like particles suitable for the detection of antiviral immune responses
CN101293099B (zh) * 2008-06-04 2010-12-08 厦门大学 一种抗多种亚型禽流感病毒的多肽疫苗及其制备方法
CN102089432A (zh) 2008-07-08 2011-06-08 麦迪卡格公司 可溶性重组流感抗原
AU2009270404B2 (en) * 2008-07-18 2015-01-29 Medicago Inc. New influenza virus immunizing epitope
US20110206727A1 (en) * 2008-07-30 2011-08-25 Denis Leclerc Multivalent Vaccines Based on Papaya Mosaic Virus and Uses Thereof
IT1394782B1 (it) 2009-03-03 2012-07-13 Alenia Aeronautica Spa Procedimento di predizione di collisioni tra un velivolo e un aeromobile
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
AU2010254136B2 (en) * 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
HRP20180706T1 (hr) 2009-06-24 2018-06-01 Medicago Inc. Kimerna gripa nalik čestici koja sadrži hemaglutinin
EP2448596B1 (en) 2009-07-02 2016-01-06 Massachusetts Institute of Technology Compositions and methods for diagnosing and/or treating influenza infection
JP5551780B2 (ja) 2009-09-22 2014-07-16 メディカゴ インコーポレイテッド 植物由来のタンパク質を調製する方法
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
JP5917402B2 (ja) 2009-11-03 2016-05-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ
CN102858368B (zh) 2010-02-18 2017-04-12 泰科诺瓦有限公司 通用病毒样颗粒(vlp)流感疫苗
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011112871A1 (en) 2010-03-11 2011-09-15 Immune Design Corp. Vaccines for pandemic influenza
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN102373184A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
CN102373182A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性囊病混合病毒样颗粒、制备方法和应用
EP2640405A4 (en) 2010-09-21 2015-04-15 Massachusetts Inst Technology HA-POLYPEPTIDES ADAPTED TO HUMANS, VACCINES THEREOF AND INFLUENZA TREATMENT THEREWITH
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
SG10201709806VA (en) 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
LT2635257T (lt) * 2010-11-05 2017-09-25 Novavax, Inc. Pasiutligės glikoproteino į virusą panašios dalelės (vlps)
CA2822443A1 (en) * 2010-12-22 2012-06-28 Novavax Inc. Modified influenza hemagglutinin proteins and uses thereof
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
EA202090699A3 (ru) 2011-07-11 2020-11-30 Такеда Вэксинс, Инк. Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
EP2739307B1 (en) 2011-08-01 2017-09-06 Emory University Vlps containing ligands and methods related thereto
CN103945863A (zh) 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
SG11201404653UA (en) 2012-02-07 2014-09-26 Univ Pittsburgh Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
CN104144941B (zh) 2012-02-13 2017-06-09 高等教育联邦系统-匹兹堡大学 以计算方式优化的人和禽h5n1流感的广泛反应性抗原
RU2485973C1 (ru) * 2012-02-28 2013-06-27 Общество с ограниченной ответственностью "НТфарма" Рекомбинантная трехвалентная вакцина от гриппа человека
CA2864733C (en) 2012-03-22 2018-09-18 Fraunhofer Usa, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
EP2831094B1 (en) 2012-03-30 2018-06-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9938324B2 (en) 2012-05-22 2018-04-10 Cornell University FRET-based reagents and methods for identifying anti-HIV compounds
JP6348489B2 (ja) 2012-06-15 2018-07-04 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質ワクチン組成物および使用方法
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CA2885741C (en) 2012-09-21 2023-10-17 Frank Bedu-Addo Vaccine comprising r-dotap
KR101484588B1 (ko) 2012-10-24 2015-01-20 대한민국 개 인플루엔자 ｖｌｐ 백신의 제조방법
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
HK1212708A1 (zh) 2012-11-27 2016-06-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education H1n1流感的計算優化的寬反應性抗原
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3033102B2 (en) 2013-08-13 2023-12-20 Northwestern University Peptide conjugated particles
CN103467581B (zh) * 2013-08-26 2016-01-20 中国科学院微生物研究所 流感病毒m1蛋白及其编码基因和应用
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CA2936350C (en) 2014-01-10 2023-01-31 Medicago Inc. Cpmv enhancer elements
RS66380B1 (sr) 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
US11273127B2 (en) * 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR101745472B1 (ko) 2015-04-15 2017-06-12 대한민국 조류인플루엔자 바이러스의 세포 감염을 저해하는 물질을 선별하는 방법
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
AU2016315478B2 (en) 2015-09-03 2023-07-13 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
EP3347044B1 (en) * 2015-09-10 2023-04-19 Academia Sinica Bird flu vaccine combination comprising virus-like particles and novel adjuvants
EP3374496A4 (en) 2015-11-13 2019-07-10 PDS Biotechnology Corporation LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
PT3661968T (pt) 2017-08-04 2022-07-04 Governing Council Univ Toronto Plataforma de nanopartículas para administração de anticorpos e vacinas
CN107353328A (zh) * 2017-08-23 2017-11-17 上海市动物疫病预防控制中心 一种重组的h9n2亚型禽流感病毒样颗粒及其制备方法和用途
CN107488216B (zh) * 2017-09-06 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 一种流感病毒通用疫苗及其制备方法与应用
CN110240634B (zh) * 2018-03-08 2022-09-06 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
CN110575538B (zh) * 2018-06-11 2022-08-19 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
CN113461786B (zh) * 2020-03-30 2022-09-13 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000885A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
BR9506885A (pt) 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
AU3760495A (en) 1994-09-30 1996-04-26 Aviron Chimeric Influenza Virus And Electroporation Method
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5945489A (en) 1997-09-19 1999-08-31 Ashland, Inc. Liquid oligomers containing unsaturation
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
US6513184B1 (en) 2000-06-28 2003-02-04 S. C. Johnson & Son, Inc. Particle entrapment system
CN100547069C (zh) * 2001-12-07 2009-10-07 克鲁塞尔荷兰公司 病毒、病毒分离物和疫苗的生产
AU2002359792A1 (en) 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) * 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000885A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6010014972; Ｖａｃｃｉｎｅ Ｖｏｌ．２０, 2002, ｐ．１２５-３３ *
JPN6011029735; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．７５, 2001, ｐ．６１５４-６５ *
JPN6011029737; Ｖａｃｃｉｎｅ Ｖｏｌ．１４, 1996, ｐ．２１９-２５ *
JPN6011029739; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．７４, 2000, ｐ．１１５３８-４７ *
JPN6014035573; 平田クリニック作成: 「インフルエンザＱ＆Ａ」 , 20010427
JPN6014035574; 八田正人ら: 「特集　感染するメカニズム，防御するメカニズム　香港Ｈ５Ｎ１インフルエンザウイルスの病原性　なぜトリイン Ｖｏｌ．２１，Ｎｏ．２, 2002, １９２〜１９７頁
JPN6014035575; Ｙ．Ｐ．Ｌｉｎ　ｅｔ　ａｌ．: 'Ａｖｉａｎ-ｔｏ-ｈｕｍａｎ　ｔｒａｎｓｍｉｓｓｉｏｎ　ｏｆ　Ｈ９Ｎ２　ｓｕｂｔｙｐｅ　ｉｎｆｌｕｅｎｚａ　Ａ　ｖｉｒｕｓｅｓ：　Ｒｅｌａｔｉｏｎｓｈｉｐ　ｂｅｔｗｅｅｎ　Ｈ９Ｎ２　ａｎｄ　Ｈ５Ｎ１' ＰＮＡＳ Ｖｏｌ．９７，　Ｎｏ．１７, 20000815, ｐｐ．９６５４-９６５８
JPN6014035576; Ｈ．Ｐｌｏｔｉｃｋｙ　ｅｔ　ａｌ．: 'Ｔｈｅ　ｉｍｍｕｎｏｄｏｍｉｎａｎｔ　ｉｎｆｌｕｅｎｚａ　ｍａｔｒｉｘ　Ｔ　ｃｅｌｌ　ｅｐｉｔｏｐｅ　ｒｅｃｏｇｎｉｚｅｄ　ｉｎ　ｈｕｍａｎ　ｉｎｄｕｃｅｓ　ｉｎｆｌｕｅｎｚａ　ｐｒｏｔｅｃｔｉｏｎ' Ｖｉｒｏｌｏｇｙ , 20030510, ｖｏｌ．３０９

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016104015A (ja) * 2009-05-01 2016-06-09 ファイザー・インク 多重遺伝子ベクターによってコードされる組換えウイルス様粒子
US12076387B2 (en) 2010-03-23 2024-09-03 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US10093703B2 (en) 2011-06-20 2018-10-09 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
US10562940B2 (en) 2011-06-20 2020-02-18 University of Pittsburgh— of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
JP2014519849A (ja) * 2011-06-20 2014-08-21 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
US11384339B2 (en) 2011-08-26 2022-07-12 Wisconsin Alumni Research Foundation (Warf) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
US12410409B2 (en) 2011-08-26 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
US11802273B2 (en) 2014-06-20 2023-10-31 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016010081A1 (ja) * 2014-07-18 2016-01-21 一般財団法人化学及血清療法研究所 ウイルス様粒子を含むワクチン
JPWO2016010081A1 (ja) * 2014-07-18 2017-04-27 一般財団法人化学及血清療法研究所 ウイルス様粒子を含むワクチン
US10525122B2 (en) 2014-07-18 2020-01-07 Km Biologics Co., Ltd. Vaccine containing virus-like particles
JP7244455B2 (ja) 2015-08-28 2023-03-22 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
JP7297832B2 (ja) 2015-08-28 2023-06-26 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
US11180737B2 (en) 2015-08-28 2021-11-23 Wisconsin Alumni Research Foundation (Warf) Generation of infectious influenza viruses from virus-like particles
JP2018530314A (ja) * 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
JP2020114250A (ja) * 2015-08-28 2020-07-30 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
JP2021184761A (ja) * 2015-08-28 2021-12-09 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
US12364748B2 (en) 2016-02-19 2025-07-22 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
US12251436B2 (en) 2017-10-25 2025-03-18 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US12144857B2 (en) 2018-08-20 2024-11-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US12258557B2 (en) 2019-02-08 2025-03-25 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US12122807B2 (en) 2019-05-01 2024-10-22 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12365880B2 (en) 2020-01-24 2025-07-22 The University Of Tokyo Recombinant influenza viruses with stabilized NA
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Also Published As

Publication number Publication date
US9956280B2 (en) 2018-05-01
CN103157103A (zh) 2013-06-19
AU2004268510A1 (en) 2005-03-10
EP1644037B1 (en) 2011-12-28
US20060263804A1 (en) 2006-11-23
HK1091118A1 (en) 2007-01-12
EP2343084A1 (en) 2011-07-13
JP2015057447A (ja) 2015-03-26
US9474799B2 (en) 2016-10-25
PL1644037T3 (pl) 2012-05-31
US8592197B2 (en) 2013-11-26
CA2532335A1 (en) 2005-03-10
US20170232095A1 (en) 2017-08-17
IL173071A (en) 2013-10-31
DK1644037T3 (da) 2012-04-10
JP2016164195A (ja) 2016-09-08
ES2422580T3 (es) 2013-09-12
US7763450B2 (en) 2010-07-27
SG165378A1 (en) 2010-10-28
SG131116A1 (en) 2007-04-26
EP1644037A4 (en) 2008-04-23
CN1849134A (zh) 2006-10-18
PT1644037E (pt) 2012-04-10
EP1644037A2 (en) 2006-04-12
US9144607B2 (en) 2015-09-29
EP2343084B1 (en) 2013-04-24
RU2369405C2 (ru) 2009-10-10
IL173071A0 (en) 2006-06-11
KR20060052804A (ko) 2006-05-19
ES2380021T3 (es) 2012-05-07
WO2005020889A3 (en) 2005-12-29
CA2532335C (en) 2014-11-18
US20050009008A1 (en) 2005-01-13
JP2013216685A (ja) 2013-10-24
AU2004268510B2 (en) 2011-06-09
BRPI0412519A (pt) 2006-09-19
MXPA06000469A (es) 2006-08-23
US20130177587A1 (en) 2013-07-11
PT2343084E (pt) 2013-07-18
PL2343084T3 (pl) 2013-09-30
NZ544580A (en) 2009-04-30
RU2006104113A (ru) 2006-07-27
DK2343084T3 (da) 2013-07-22
WO2005020889A2 (en) 2005-03-10
US20150306206A1 (en) 2015-10-29
JP2011046715A (ja) 2011-03-10
ATE538810T1 (de) 2012-01-15
CN107513102A (zh) 2017-12-26
KR101153929B1 (ko) 2012-07-05

Similar Documents

Publication Publication Date Title
JP2016164195A (ja) 機能的インフルエンザウイルス様粒子（ｖｌｐ）
US9180180B2 (en) Functional influenza virus-like particles (VLPs)
EP1937301B1 (en) Functional influenza virus like particles (vlps)
US8506967B2 (en) Functional influenza virus like particles (VLPs)
AU2011218606B2 (en) Functional influenza virus-like particles (VLPS)
HK1091118B (en) Functional influenza virus-like particles (vlps)
HK1194099A (en) Functional influenza virus like particles (vlps)

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100623

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121116

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150622

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20151210